Company environment · Targeted small molecules · multi-market
Multi-market targeted oncology NDA & EMA lifecycle
Lifecycle snapshots spanning IND Fast Track, NDA approval, and EMA post-approval commitments.
1What does this company do?
Originator oncology sponsor managing a targeted small molecule from IND expedited-program strategy through FDA approval and EU post-authorization commitments.
2Where is the product on its way to patients?
Oral targeted kinase inhibitor across US NDA approval, EMA variation, and supplemental indication expansion.
- 1Discovery & Lead Selection
- 2IND-Enabling Nonclinical
- 3Clinical Development (IND / CTA)
- 4Registration & Dossier Review
- 5Approval & Launch Readiness
- 6Commercial Lifecycle & GMP
- The product is here
3What is happening right now?
Four dated regulatory gates across US and European filings.
4Tasks
4 tasks in the 81-task Biopharma Bench V0.2 suite, graded against expert rubric criteria.
Sealed partner records & open showcases
This environment is reconstructed from a confidential drug or device program, so its records, tasks, and rubrics remain sealed.
To inspect complete workspaces, candidate deliverables, trajectories, and rubric criteria end to end, open the two public companion showcases:
Havenor Therapeutics (synthetic sterile-injectables CMC/MSAT) →
Broad Institute (public FDA CDER IND 167326 record) →